Journal: Annals of Hematology

Article Title: Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma

doi: 10.1007/s00277-025-06571-z

Figure Lengend Snippet: Maprotiline inhibits the proliferation and migration of TCL cells. A The chemical structure of maprotiline. B Jurkat, H9, Hut-78, and HH cells were treated with concentrations of maprotiline, and cell viability was detected using the CCK-8 assay. C The migration abilities of Jurkat and H9 cells treated with maprotiline (0, 10, or 20 µM) for 24 h were determined by chamber migration assays. D Morphological changes in Jurkat and H9 cells were observed under a microscope after treatment with different concentrations of maprotiline for 72 h. Scale bars, 50 μm. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The human TCL cell lines (Jurkat, H9, Hut-78, and HH) were ordered from the American Type Culture Collection.

Techniques: Migration, CCK-8 Assay, Microscopy

Journal: Annals of Hematology

Article Title: Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma

doi: 10.1007/s00277-025-06571-z

Figure Lengend Snippet: Maprotiline induces apoptosis in TCL cells. A The apoptosis in Jurkat and H9 cells treated with different concentrations of maprotiline for 48 h was detected by flow cytometry. B Western blot was performed to detect cleaved caspase-3, caspase-3, and cleaved PARP levels in cells treated with maprotiline for 48 h. C , D Jurkat and H9 cells were pre-incubated with or without Z-VAD-FMK (50 µM) for 1 h, then treated with maprotiline (20 µM), cell viability was detected by the CCK-8 assay (72 h) and apoptosis-related proteins were detected by Western blot assay (48 h). E Flow cytometry results illustrating that Z-VAD-FMK (50 µM) effectively reverses maprotiline (10 µM)-induced apoptosis in Jurkat and H9 cells. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The human TCL cell lines (Jurkat, H9, Hut-78, and HH) were ordered from the American Type Culture Collection.

Techniques: Flow Cytometry, Western Blot, Incubation, CCK-8 Assay

Journal: Annals of Hematology

Article Title: Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma

doi: 10.1007/s00277-025-06571-z

Figure Lengend Snippet: Maprotiline exerts an antitumor effect in TCL by inhibiting the AKT/mTOR signaling pathway. A Differential gene analysis of TCL cells treated by maprotiline or control. B KEGG pathway enrichment analysis of differentially expressed genes. C Western blot analysis of p-AKT, AKT, p-mTOR, mTOR, p-S6K1, S6K1, p-4EBP1, and 4EBP1 protein levels in Jurkat and H9 cells following maprotiline treatment for 48 h. D , E Jurkat and H9 cells were pretreated with 8 µM AKT activator (SC79) for 1 h prior to maprotiline (20 µM) exposure. Protein levels of p-AKT, AKT, p-mTOR, mTOR, p-S6K1, S6K1, p-4EBP1, and 4EBP1 were assessed by Western blot after 48 h, and cell viability was determined by CCK-8 assay at 72 h. F SC79 (8 µM) attenuates the inhibitory effect of maprotiline (20 µM) on Jurkat and H9 cell migration. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The human TCL cell lines (Jurkat, H9, Hut-78, and HH) were ordered from the American Type Culture Collection.

Techniques: Control, Western Blot, CCK-8 Assay, Migration

Journal: Annals of Hematology

Article Title: Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma

doi: 10.1007/s00277-025-06571-z

Figure Lengend Snippet: Maprotiline increases the sensitivity of TCL cells to histone deacetylase inhibitors. A Cell viability of Jurkat and H9 cells treated with maprotiline (10 µM), chidamide (0.5 µM), or the combination of both was determined by CCK-8 assay. B Cell viability of Jurkat and H9 cells treated with maprotiline (10 µM), belinostat (0.2 µM), or the combination of both was determined by CCK-8 assay. C Flow cytometry analysis revealed that maprotiline (10 µM) significantly enhances chidamide (0.5 µM)-induced apoptosis in TCL cells at 48 h. D-E Jurkat and H9 cells were incubated with maprotiline (10 µM), chidamide (0.5 µM), or the combination of both for 48 h, the levels of caspase-3, cleaved caspase-3, cleaved PARP ( D ), and AKT, AKT, p-mTOR, mTOR, p-S6K1, S6K1, p-4EBP1, 4EBP1 ( E ) were analyzed by Western blot assay. ** p < 0.01, *** p < 0.001

Article Snippet: The human TCL cell lines (Jurkat, H9, Hut-78, and HH) were ordered from the American Type Culture Collection.

Techniques: Histone Deacetylase Assay, CCK-8 Assay, Flow Cytometry, Incubation, Western Blot